Case study on phenylketonuria: a memic autism
Abstract
Phenylketonuria (PKU) is a phenylalanine catabolism metabolic condition characterized by a decrease in the activity of the phenylalanine hydroxylase or Dihydro pteridine reductase enzyme. This inherited condition causes a build-up of phenylalanine in the bloodstream. Elevated phenylalanine levels in the blood can cause muscle rigidity, choreoathetosis, tremors, hyperreflexia, dermatitis, pale skin, and pseudo-scleroderma. The central nervous system deficiencies in PKU are caused by phenylalanine and phenyl pyruvic acid competing for dopamine, adrenaline, norepinephrine, and serotonin in the brain. Structural changes are caused by neurotransmitter inhibition and phenylalanine and phenyl pyruvic accumulations in the white matter of the posterior periventricular, frontal, and subcortical areas of the brain1. Greater myelin turnover decreased synaptogenesis, and reduced neuronal digenesis ensues from myelin deficit, resulting in cognitive development and mental retardation1. The patient in this case study is an 8-year-old boy who has been diagnosed with phenylketonuria. The patient’s parents had a history of consanguinity marriage. The patient has had seizures since he was nine months old. Speech and language delays, hearing loss, and tooth discoloration are all common symptoms. He had an MRI and a brain scan, as well as a blood amino acids test, which revealed that he has mild developmental delays. Mild to Moderate Autistic Features is Delayed.
Downloads
References
2. Specific Genetic Disorders and Autism: Clinical Contribution Towards their Identification David Cohen,1,7 Nade`ge Pichard,2 Sylvie Tordjman,2 Clarisse Baumann,3 Lydie Burglen,4 Elsa Excoffier,5 Gabriela Lazar,1 Philippe Mazet,1 Cle’ment Pinquier,1 Alain Verloes,3 and Delphine He´ron6.
3. International Journal of Health Sciences & Research (www.ijhsr.org) 308 Vol.4; Issue: 7; July 2014 International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Case Report Phenylketonuria with Autism Spectrum Disorders- A Case Study V. Suresh Kumar Head, Neonatal Screening Laboratory, Neopel Bioscience Pvt. Ltd, Chennai, Tamilnadu, India.
4. Risperidone or Aripiprazole Can Resolve Autism Core Signs And Symptoms in Young Children: Case Study Hamza A. Alsayouf 1,* , Haitham Talo 1, Marisa L. Biddappa 1 and Emily De Los Reyes 2.
5. van Wegberg AMJ, MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis 2017; 12:162.
6. https://www.uptodate.com/contents/overview-of-phenylketonuria/abstract/6van Wegberg AMJ, MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis 2017; 12:162.
7. Food and Drug Administration. Approval for Risperdal (Risperidone) in Treatment of the Irritability Associated with Autistic Disorder. 2006. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020272Orig1s036,s041,02058 8Orig1s024,s028,s029,21444Orig1s008,s015.pdf (accessed on 18 December 2020).
8. Bristol Myers Squibb. U.S. Food and Drug Administration Approves ABILIFY® (Aripiprazole) for the Treatment Of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years). 2009. Available online:https://news.bms.com/news/details/2009/US-Food-and-Drug-Administration-Approves-ABILIFY-aripiprazole-for-the-Treatment-of-Irritability-Associated-with-Autistic-Disorder-in-Pediatric-Patients-Ages-6-to-17-Years/default.aspx

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
drnagaraju.gv@gmail.com


.